Acadian Asset Management LLC Sells 24,459 Shares of Regenxbio Inc (RGNX)

Acadian Asset Management LLC cut its holdings in Regenxbio Inc (NASDAQ:RGNX) by 34.5% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,407 shares of the biotechnology company’s stock after selling 24,459 shares during the period. Acadian Asset Management LLC owned about 0.14% of Regenxbio worth $3,503,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Meadow Creek Investment Management LLC purchased a new position in Regenxbio in the 2nd quarter valued at about $141,000. Meeder Asset Management Inc. lifted its holdings in Regenxbio by 1,212.0% in the 2nd quarter. Meeder Asset Management Inc. now owns 2,178 shares of the biotechnology company’s stock valued at $156,000 after purchasing an additional 2,012 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Regenxbio in the 2nd quarter valued at about $157,000. Glen Harbor Capital Management LLC purchased a new position in Regenxbio in the 2nd quarter valued at about $171,000. Finally, SG Americas Securities LLC purchased a new position in Regenxbio in the 2nd quarter valued at about $179,000. Institutional investors and hedge funds own 81.17% of the company’s stock.

In other news, SVP Patrick J. Christmas sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $72.06, for a total transaction of $1,080,900.00. Following the completion of the transaction, the senior vice president now owns 2,669 shares of the company’s stock, valued at approximately $192,328.14. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Patrick J. Christmas sold 5,000 shares of the company’s stock in a transaction dated Monday, August 20th. The shares were sold at an average price of $65.96, for a total transaction of $329,800.00. Following the transaction, the senior vice president now directly owns 22,669 shares of the company’s stock, valued at approximately $1,495,247.24. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 286,585 shares of company stock valued at $18,814,681. Corporate insiders own 16.90% of the company’s stock.

NASDAQ RGNX opened at $66.37 on Friday. Regenxbio Inc has a 12 month low of $23.25 and a 12 month high of $85.10. The stock has a market cap of $2.25 billion, a PE ratio of -27.09, a P/E/G ratio of 13.98 and a beta of -0.49.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.56) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.30. Regenxbio had a net margin of 44.44% and a return on equity of 28.70%. The company had revenue of $5.31 million during the quarter. Sell-side analysts forecast that Regenxbio Inc will post 1.64 earnings per share for the current year.

RGNX has been the topic of a number of recent research reports. Morgan Stanley upped their target price on shares of Regenxbio from $37.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, July 13th. Chardan Capital upped their target price on shares of Regenxbio from $90.00 to $130.00 and gave the company a “buy” rating in a report on Monday, July 16th. Bank of America lowered shares of Regenxbio from a “buy” rating to a “neutral” rating and upped their target price for the company from $64.00 to $80.00 in a report on Monday, July 23rd. BidaskClub lowered shares of Regenxbio from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 25th. Finally, ValuEngine upgraded shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a report on Friday, August 10th. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $84.07.

COPYRIGHT VIOLATION WARNING: This news story was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright law. The original version of this news story can be read at https://www.americanbankingnews.com/2018/11/10/acadian-asset-management-llc-sells-24459-shares-of-regenxbio-inc-rgnx.html.

Regenxbio Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Featured Article: Day Trading

Want to see what other hedge funds are holding RGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regenxbio Inc (NASDAQ:RGNX).

Institutional Ownership by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply